Ann: onCARlytics to be showcased in three abstracts at SITC, page-73

Thanks for posting @Glouva and thanks for sharing @microcapguru.

Brilliant business move by Imugene to use Amgens Blinatumomab in one of the pre clinical trials in my opinion.

- As Blinatumomab is already in use this means Imugene have data to fall back on if ARTEMIS® and CYCART-19 fall down in trials....

- Potential fast track to market as its already an approved drug.

- OnCARlytics can no doubt be used with other CAR-T therapies so there will be demand.

It's all systems go at Imugene and the team always seems to be one step ahead. Looking forward to seeing OnCARlytics hit patients next year.